Compare Hewlett Packard Enterprise Co (HPE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Neurocrine Biosciences Inc — how do they compare? Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Hewlett Packard Enterprise Co is far larger — about 6.6× Neurocrine Biosciences Inc's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HPE | NBIX | |
|---|---|---|
Market Cap | $94.25B | $14.36B |
Volume | 16,060,854 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $72.12 | $185.50 |
52-Week Low | $20.01 | $123.10 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $108.28B | $14.37B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE's stock trades at $70.99, down 1.56% today but near its 52-week high, with a bullish technical outlook and strong AI-driven momentum. Recent earnings beats and a $1.2B AI server order from Vultr highlight robust demand. Valuation metrics show a P/E of 36.6 and P/S of 2.4, while cash flow trends indicate volatility with a net outflow of $9.25B in 2025 but a projected rebound in 2026.
The outlook is positive, driven by AI infrastructure growth and raised guidance, but risks include high debt levels and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting cautious optimism amid near-term overbought conditions.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
